

WEST Search History

DATE: Monday, September 22, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>			
L11	l9 and l7	7	L11
L10	l9 and l6	0	L10
L9	L8 and anti-idiotypic with (anti-HIV or antibody with HIV\$4 or AIDS or immunodeficiency adj virus)	7	L9
L8	L7 not l6	215	L8
L7	l3 and anti-idiotypic with (DNA or polynucleotide or nucleic adj acid) same (antibody or variable adj regions or CDR or FR)	218	L7
L6	L5 and (DNA or polynucleotide or nucleic adj acid) same (antibody or variable adj regions or CDR or FR)	18	L6
L5	l2 and l3	25	L5
L4	l2 and l3L3	0	L4
L3	anti-idiotypic with antibody and antibody with (anti-HIV or antibody with HIV\$4 or AIDS or immunodeficiency adj virus)	920	L3
L2	(1F7 or IF7 or (accession or ATCC) with (HB11286 or HB adj 11286)) and antibody	56	L2
<i>DB=USPT; PLUR=YES; OP=OR</i>			
L1	(1F7 or IF7 or (accession or ATCC) with (HB11286 or HB adj 11286)) and antibody	30	L1

END OF SEARCH HISTORY

STM Search History

FILE 'HOME' ENTERED AT 13:01:02 ON 22 SEP 2003

L1 21945 IF7 OR 1F7 OR (ANTI-IDIOTYPIC OR ANTIIDIOTYPIC (S) ANTIBODY AND
(HIV## OR AIDS OR IMMUNODEFICIENCY(S) VIRUS))

L2 19888 L1 AND ANTIBODY (P) (ANTI-IDIOTYPIC OR ANTIIDIOTYPIC)

L4 39 L3 AND (HUMANIZ##### OR POLYNUCLEOTIDE OR NUCLEIC (A) ACID
OR DNA OR VECTOR)

(FILE 'HOME' ENTERED AT 13:01:02 ON 22 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 13:01:30 ON
22 SEP 2003

L1 21945 S IF7 OR 1F7 OR (ANTI-IDIOTYPIC OR ANTIIDIOTYPIC (S) ANTIBODY

L2 19888 S L1 AND ANTIBODY (P) (ANTI-IDIOTYPIC OR ANTIIDIOTYPIC)

L3 304 S L2 AND ANTI-IDIOTYPIC (P) (HIV##)

L4 39 S L3 AND (HUMANIZ##### OR POLYNUCLEOTIDE OR NUCLEIC (A) ACID

L5 26 DUP REM L4 (13 DUPLICATES REMOVED)

L6 17 S L5 NOT PY> 2001

L6 ANSWER 1 OF 17 MEDLINE on STN
 TI Cloning and sequence analysis of cDNAs encoding the heavy and light chain variable regions of an Ab2beta **anti-idiotypic** monoclonal **antibody** possessing an internal image of cocaine.
 AU Ho M; Segre M
 SO BIOCHIMICA ET BIOPHYSICA ACTA, (2001 Oct 31) 1521 (1-3) 135-40.
 Journal code: 0217513. ISSN: 0006-3002..

L6 ANSWER 2 OF 17 MEDLINE on STN
 TI B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions.
 AU Biragyn A; Kwak L W
 SO IMMUNOLOGICAL REVIEWS, (1999 Aug) 170 115-26. Ref: 97
 Journal code: 7702118. ISSN: 0105-2896.

L6 ANSWER 3 OF 17 MEDLINE on STN
 TI **Anti-idiotypic antibody** to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of **HIV-1** infection cycle.
 AU Thomas E K; Connelly R J; Pennathur S; Dubrovsky L; Haffar O K; Bukrinsky M I
 SO VIRAL IMMUNOLOGY, (1996) 9 (2) 73-87.
 Journal code: 8801552. ISSN: 0882-8245.

L6 ANSWER 4 OF 17 MEDLINE on STN
 TI Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.
 AU Lopalco L; Longhi R; Ciccomascolo F; De Rossi A; Pelagi M; Andronico F; Moore J P; Schulz T; Beretta A; Siccardi A G
 SO AIDS RESEARCH AND HUMAN RETROVIRUSES, (1993 Jan) 9 (1) 33-9.
 Journal code: 8709376. ISSN: 0889-2229.

L6 ANSWER 5 OF 17 MEDLINE on STN
 TI Molecular cloning of murine monoclonal **anti-idiotypic** Fab.
 AU Kasai Y; Herlyn D; Sperlagh M; Maruyama H; Matsushita S; Linnenbach A J
 SO JOURNAL OF IMMUNOLOGICAL METHODS, (1992 Oct 19) 155 (1) 77-89.
 Journal code: 1305440. ISSN: 0022-1759.

L6 ANSWER 6 OF 17 MEDLINE on STN
 TI Sequence analysis of the variable region of a mouse gene encoding a monoclonal **anti-idiotypic antibody** that detects a restricted idioype on anti-**HIV-1** gp160.
 AU Lohman K L; Carrillo M A; Kennedy R C
 SO GENE, (1991 Sep 15) 105 (2) 283-4.
 Journal code: 7706761. ISSN: 0378-1119.

L6 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
 TI Human monoclonal antibodies to HIV-1 envelope glycoprotein gp120
 IN Watkins, Brynmor A.; Rietz, Marvin S., Jr.
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2

L6 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
 TI A novel chimeric protein for prevention and treatment of HIV infection
 IN Berger, Edward A.; Del Castillo, Christie M.
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2

- L6 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
 TI Variable heavy and light chain regions of murine monoclonal antibody
1F7
 IN Muller, Sybille; Kohler, Heinz
 SO U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 351,193, abandoned.
 CODEN: USXXAM
- L6 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
 TI Use of a LESTR/fusin/CXCR4 receptor ligand chemokine SDF-1 for treating or
 preventing HIV infection
 IN Arenzana-Seisdedos, Fernando; Virelizier, Jean-Louis; Baggiolini, Marco;
 Moser, Bernhard; Clark-Lewis, Ian
 SO PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
- L6 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
 TI Treatment of **HIV**-infected patients by removal of anti TCR-Vbeta
 autoantibodies from blood
 IN Primi, Daniele
 SO U.S., 43 pp., Division of U.S. Ser. No. 408,011.
 CODEN: USXXAM
- L6 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
 TI Selection human **anti-idiotypic antibody**
 against LPS of Shigella sonnei and characteristics of heavy chain gene
 AU Liu, Huaitian; Wang, Haitao; Huang, Ce; Yu, Xiaofeng; Wang, Xue
 SO Junshi Yixue Kexueyuan Yuankan (1996), 20(4), 255-258
 CODEN: JYKYEL; ISSN: 1000-5501
- L6 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
 TI Monoclonal antibodies neutralizing **HIV**-1, immunogenic peptides,
 and their preparation and use in prophylaxis and treatment of **HIV**
 -1 infection
 IN Chang, Tse Wen; Fung, Sek C.; Sun, Cecily Rou Yun; Sun, Bill Nai Chau;
 Chang, Nancy T.; Liou, Ruey Shyan; Rosen, Edward M.
 SO PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
- L6 ANSWER 14 OF 17 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 TI Vaccines, vaccination and the immune response.
 AU Ada, Gordon; Ramsay, Alistair
 SO Ada, G.; Ramsay, A.. (1997) pp. xiii+247p. Vaccines, vaccination and the
 immune response.
 Publisher: Lippincott-Raven Publishers 227 East Washington Square,
 Philadelphia, Pennsylvania 19106, USA.
 ISBN: 0-397-58761-9.
- L6 ANSWER 15 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 TI Expansion of epitope cross-reactivity by anti-idiotypic modulation of the
 primary humoral response.
 AU Denisova G.F.; Zerwanitzer M.; Denisov D.A.; Spectorman E.; Mondor I.;
 Sattentau Q.; Gershoni J.M.
 SO Molecular Immunology, (2000) 37/1-2 (53-58).
 Refs: 22
 ISSN: 0161-5890 CODEN: IMCHAZ
- L6 ANSWER 16 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 TI DUAL-SPECIFICITY OF A MONOCLONAL **ANTIIDIOTYPIC ANTIBODY**
 FOR **HIV**-1 NEUTRALIZING MONOCLONAL-110.3 AND MONOCLONAL-110.4 AS
 WELL AS THE V3 LOOP OF GP120

AU CONNELLY R J (Reprint); KAHN M; BLAKE J; HAFFAR O K; THOMAS E K
SO VIROLOGY, (DEC 1994) Vol. 205, No. 2, pp. 554-557.
ISSN: 0042-6822.

L6 ANSWER 17 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI GENERATION AND SPECIFICITY OF MONOCLONAL **ANTIIDIOTYPIC**
ANTIBODIES AGAINST HUMAN **HIV**-SPECIFIC **ANTIBODIES**
.1. CROSS-REACTING IDIOTOPES ARE EXPRESSED IN SUBPOPULATIONS OF
HIV-INFECTED INDIVIDUALS

AU MULLER S; WANG H T; KAVERI S V; CHATTOPADHYAY S; KOHLER H (Reprint)
SO JOURNAL OF IMMUNOLOGY, (1991) Vol. 147, No. 3, pp. 933-941.

ANSWER 3 OF 17 MEDLINE on STN

AN 96419925 MEDLINE

DN 96419925 PubMed ID: 8822624

TI **Anti-idiotypic antibody** to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of **HIV-1** infection cycle.

AU Thomas E K; Connelly R J; Pennathur S; Dubrovsky L; Haffar O K; Bukrinsky M I

CS Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA.

NC AI 33776 (NIAID)

SO VIRAL IMMUNOLOGY, (1996) 9 (2) 73-87.
Journal code: 8801552. ISSN: 0882-8245.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; AIDS

EM 199612

ED Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961203

AB Although the CD4 molecule is the major cellular receptor for human **immunodeficiency virus (HIV)**, several lines of evidence suggest participation of additional molecules that are engaged after the binding of **HIV** to the CD4 receptor and that may facilitate viral entry into the target cell. Some of the post-CD4 binding, perfusion events involve the third hypervariable region (V3 loop) of the viral envelope protein gp120. To identify cellular proteins that interact with the V3 loop, we chose as a probe an **antiidiotypic monoclonal antibody (MAb)**, anti-id2, which was prepared against the neutralizing MAb 110.4 that binds the V3 domain in the envelope glycoprotein gp120 of the LAI isolate of **HIV-1**. Anti-id2 reacted specifically with a 55- to 60-kDa protein in human T cell and monocytoid cell lines, and in a mouse melanoma cell line. This protein was identified immunologically and by protein sequence analysis as vimentin, an intermediate filament protein of lymphoid and other cells of mesodermal origin. Antiserum raised against vimentin inhibited nuclear translocation of **HIV-1 DNA** following infection of monocytes and CD4+ T cells with live virus, and reduced the amount of **HIV-1 gag-specific RNA** in the nuclei of monocytes following inoculation with **HIV-1** pseudovirions. These data suggest that vimentin may participate in the early steps of **HIV-1** replication, perhaps during the uptake of **HIV-1** preintegration complexes into the nuclear compartment.

L6 ANSWER 4 OF 17 MEDLINE on STN

AN 93152284 MEDLINE

DN 93152284 PubMed ID: 7678970

TI Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.

AU Lopalco L; Longhi R; Ciccomascolo F; De Rossi A; Pelagi M; Andronico F; Moore J P; Schulz T; Beretta A; Siccardi A G

CS Centro San Luigi H.S.R. Milano, Italy.

SO AIDS RESEARCH AND HUMAN RETROVIRUSES, (1993 Jan) 9 (1) 33-9.
Journal code: 8709376. ISSN: 0889-2229.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; AIDS

EM 199303

ED Entered STN: 19930326
 Last Updated on STN: 19970203
 Entered Medline: 19930305

AB A sequence of four amino acid residues amino-terminal to the only intramolecular disulphide bond of the human immunodeficiency virus type 1 (HIV-1) transmembrane protein gp41 is recognized by an **anti-idiotypic antibody** (9G5A) raised against another monoclonal **antibody** (M38), which recognizes the C5 region of gp120. 9G5A is an Ab2 beta **antibody** (internal image of the M38 epitope) in that it inhibits the interaction of M38 to its antigen. The binding of 9G5A to gp41 can be inhibited by M38 showing that the two **antibodies** interact via their paratopes. 9G5A neutralizes HIV-1 infection and syncytia formation. Ab3 **antibodies** induced in mice and rabbits immunized with 9G5A also can neutralize virus in both assays. These data show that the M38-defined epitope of the carboxy-terminal region of gp120 interacts with the 9G5A-defined epitope of gp41, and that this interaction can be reproduced by the idiotypic mimicry of the two **antibodies**. The results are consistent with a proposed molecular model of the two env regions which predicts the presence, within the C5 region of gp120, of a large intramolecular pocket that is contacted by the gp41 cysteine loop.

L6 ANSWER 5 OF 17 MEDLINE on STN
 AN 93017981 MEDLINE
 DN 93017981 PubMed ID: 1383347
 TI Molecular cloning of murine monoclonal **anti-idiotypic** Fab.

AU Kasai Y; Herlyn D; Sperlagh M; Maruyama H; Matsushita S; Linnenbach A J
 CS Wistar Institute of Anatomy and Biology, Philadelphia, PA 19104.
 NC AI25380-02 (NIAID)
 CA10815 (NCI)

SO JOURNAL OF IMMUNOLOGICAL METHODS, (1992 Oct 19) 155 (1) 77-89.
 Journal code: 1305440. ISSN: 0022-1759.

CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; AIDS
 EM 199211
 ED Entered STN: 19930122
 Last Updated on STN: 19970203
 Entered Medline: 19921116

AB **Anti-idiotypic antibodies** (Ab2) binding to idiotopes on **antibodies** with various antigen binding specificities (Ab1) are potential regulators of immunity in a variety of diseases, such as autoimmunity, cancer, and viral, bacterial, or parasitic infections. Furthermore, Ab2 are useful probes for the characterization of receptor/ligand interactions. Thus far, Ab2 production has been limited to the isolation of polyclonal Ab2 from immune sera or monoclonal Ab2 from hybridoma supernatants. However, both approaches have produced a limited number of Ab2. As an alternative approach, we demonstrate here the production of Ab2-Fab by using repertoire cloning. Using HIV-1 as a model system, the Ab2-Fab were generated from the spleens of mice immunized with the virus-neutralizing and syncytia-inhibiting anti-HIV-1 monoclonal **antibody** 0.5 beta. A bacteriophage lambda **vector** system was used to express a combinatorial library in Escherichia coli. Iodinated 0.5 beta was used to identify 17 Ab2-Fab clones. DNA sequence analysis of five clones revealed three similar kappa and Fd combinations. The Ab2-Fab bound with high affinity ($3.5-6.5 \times 10^9$ liters/mol) specifically to the Ab1 and not to isotype-matched **antibodies** with unrelated specificities. The three Ab2-Fab probably bind to the same idiotope on the Ab1 as

demonstrated in cross-competition binding studies. The Ab2-Fab inhibited binding of the Abl to antigen, and therefore, may functionally mimic the epitope defined by the Abl. Repertoire cloning of Ab2-Fab may facilitate the generation of Ab2 that have potential as modulators of immune responses against various antigens.

L6 ANSWER 6 OF 17 MEDLINE on STN
 AN 92039046 MEDLINE
 DN 92039046 PubMed ID: 1937027
 TI Sequence analysis of the variable region of a mouse gene encoding a monoclonal **anti-idiotypic antibody** that detects a restricted idiootype on anti-**HIV-1** gp160.
 AU Lohman K L; Carrillo M A; Kennedy R C
 CS Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, TX 78228-0147.
 NC AI26462 (NIAID)
 SO GENE, (1991 Sep 15) 105 (2) 283-4.
 Journal code: 7706761. ISSN: 0378-1119.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; AIDS
 OS GENBANK-M59725; GENBANK-M59726; GENBANK-M59727; GENBANK-M59728; GENBANK-M59984; GENBANK-M59985; GENBANK-M63990; GENBANK-S61507; GENBANK-S63856; GENBANK-S63863
 EM 199112
 ED Entered STN: 19920124
 Last Updated on STN: 19970203
 Entered Medline: 19911213
 AB We have sequenced the cDNAs encoding the variable (V) regions from the light and heavy chains of a monoclonal **anti-idiotypic antibody** (Ab), designated MC1, that, when used as an immunogen, activates regulatory idiotypes associated with anti-**HIV-1** gp 160 responses. This anti-Id represents a non-antigen-mimicking subclass of Ab-2 referred to as non-internal image. The gene family selections and sequence homologies are presented.

L6 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:284017 CAPLUS
 DN 132:320942
 TI Variable heavy and light chain regions of murine monoclonal antibody **1F7**
 IN Muller, Sybille; Kohler, Heinz
 PA Immpheron, Inc., USA
 SO U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 351,193, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6057421	A	20000502	US 1997-984277	19971203
	GB 2346876	A1	20000823	GB 2000-11946	19981015
	GB 2346876	B2	20010912		
	AU 741064	B2	20011122	AU 1999-10928	19981015
PRAI	US 1994-351193	B2	19941130		
	US 1997-984227	A	19971203		
	WO 1998-US21861	W	19981015		

AB The amino acid sequences of variable heavy and variable light domains of murine monoclonal antibody **1F7** are reported. Methods of use for products contg. these sequences in the diagnosis and the treatment of

HIV infection and **AIDS** are also described.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:622807 CAPLUS

DN 127:257610

TI Treatment of **HIV**-infected patients by removal of anti TCR-Vbeta autoantibodies from blood

IN Primi, Daniele

PA Consorzio per le Biotecnologie, Italy

SO U.S., 43 pp., Division of U.S. Ser. No. 408,011.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5665355	A	19970909	US 1995-488212	19950607
	US 5891623	A	19990406	US 1994-320306	19941006
	US 5928642	A	19990727	US 1994-408011	19941018
	US 5925513	A	19990720	US 1995-488209	19950607

PRAI US 1992-973485 19921109
US 1994-408011 19941018

AB The invention provides a method of treatment of a person infected with **HIV** to attenuate or avert immunodeficiency which involves removing an **antibody** capable of binding to an epitope on TCR-V.beta. from the blood of a person infected with **HIV**. In addn., assays for the presence or absence of CD4+ T cell subpopulations carrying particular V.beta. components of the T cell receptor (TCR-V.beta.) in persons infected with **HIV**, including amplification of mRNA from T cells with primers specific to each TCR-V.beta. to detect the presence or absence of each TCR-V.beta. in a sample and primers for use in such amplification assays are disclosed. Assays of **antibody**-contg. fluids (such as blood) of a person infected with **HIV** to det. the immunodeficiency where the fluid is suspected to contain an **antibody** having a paratope specific to an epitope on a TCR-V.beta. are further disclosed. A binding agent specific to a paratope where the paratope is specific to an epitope on a TCR-V.beta. is provided. A method of assay of the fluids of a person infected with **HIV** to det. the immunodeficiency of the person which utilizes a binding agent specific to complexes contg. anti-TCR-V.beta. **antibody** bound to TCR-V.beta. is presented. A method of treatment of a person infected with **HIV** to attenuate or avert immunodeficiency which utilize a binding agent that is homologous with an epitope on TCR-V.beta. is proposed. A method of vaccination of a person infected or at risk for infection with **HIV** which raises **antiidiotypic antibodies** specific to free **antibodies** contg. a paratope specific to an epitope on a TCR-V.beta. is further proposed.

L6 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1989:572324 CAPLUS

DN 111:172324

TI Monoclonal antibodies neutralizing **HIV**-1, immunogenic peptides, and their preparation and use in prophylaxis and treatment of **HIV**-1 infection

IN Chang, Tse Wen; Fung, Sek C.; Sun, Cecily Rou Yun; Sun, Bill Nai Chau; Chang, Nancy T.; Liou, Ruey Shyan; Rosen, Edward M.

PA Tanox Biosystems, Inc., USA; Baylor College of Medicine

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8809181	A2	19881201	WO 1988-US1797	19880527
	WO 8809181	A3	19890209		
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 366718	A1	19900509	EP 1988-906589	19880527
	EP 366718	B1	19950510		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 03504556	T2	19911009	JP 1988-506387	19880527
	JP 2520464	B2	19960731		
	AT 122237	E	19950515	AT 1988-906589	19880527
	CA 1339857	A1	19980505	CA 1988-567904	19880527
PRAI	US 1987-57445		19870529		
	US 1987-137861		19871224		
	US 1988-197766		19880523		
	WO 1988-US1797		19880527		

AB Monoclonal **antibodies** (MAb) which neutralize human **immunodeficiency virus** type 1 (**HIV-1**), inhibit the rate of infection of T-cells, and also inhibit syncytium formation, are prepd. by the hybridoma method. The Ab are group-specific and neutralize different strains and isolates. These MAb, chimeric MAb and Ig, and bispecific **antibodies**, their **HIV-1** glycopeptide gp120 peptide epitopes, and **anti-idiotypic** MAb may be used in the treatment and prevention of **AIDS** and **AIDS**-related complex(ARC). Chimeric viral-neutralizing **antibodies**, fused genes encoding a chimeric Ig, and **antibody** conjugates are also disclosed. MAb BAT085, -123, -267, -509, and -496 inhibited the infection of H9 cells by **HIV-1** with IC50 values of 100, 10, 10, 30, and 1 times. 105 ng/mL, resp. At 10 .mu.g/mL the MAb inhibited syncytia formation between **HIV** -infected H9 cells and HeLa T4 cells by 24.6, 72.0, 50.2, 48.5, and 5.1%, resp. The MAb were prepd. by the hybridoma method using inactivated **HIV-1** as immunogen.